aTyr Pharma posts $107.9M cash; FDA path for efzofitimod registrational trial in Q3 2022

aTYR PHARMA INC

Cash, cash equivalents and investments of $107.9M as of Dec 31, 2021.
FDA End-of-Phase 2 meeting provides development pathway; registrational trial for efzofitimod in pulmonary sarcoidosis planned to start Q3 2022.
Orphan drug designation granted for efzofitimod in sarcoidosis.
ATYR2810 Phase 1 study expected to initiate in H2 2022.
R&D expenses $23.3M in 2021, expected to increase in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.